- Details
- Shilpa Gupta shares significant insights on the EV-103 study focused on the four-year outcomes of enfortumab vedotin (EV) and pembrolizumab as a frontline treatment for locally advanced or metastatic urothelial cancer patients who are cisplatin ineligible. Dr. Gupta discusses the 73% response rates, median overall survival exceeding two years, and over 41% of patients remaining progression-free af...
|
- Details
- Rafee Talukder discusses his presentation on his research into the effects of MTAP loss on survival rates among advanced urothelial cancer patients undergoing immunotherapy. With the help of an extensive international database, his team found that patients with this MTAP loss exhibited worse observed response rates and a trend toward poorer progression-free survival. In addition, the conversation...
|
- Details
- Alicia Morgans speaks with Jonathan Rosenberg about the approval of the combination of Enfortumab vedotin (EV) and Pembrolizumab for urothelial carcinoma treatment. Dr. Rosenberg notes the impressive response rates (64.5%) from the combination, as compared to EV monotherapy (45%), and highlights the promising survival rates, which significantly exceed expectations for a cisplatin-eligible populati...
|
- Details
- Petros Grivas elaborates on the structure, work, and initiatives of the ECOG-ACRIN Cooperative Group, emphasizing its diverse committees and its collaboration with the NCI. He highlights the Group's exploration of targeted therapies and non-immunotherapy combinations, especially through their innovative ComboMATCH program, designed to overcome resistance to single-agent targeted therapies. Grivas...
|
- Details
- Tanya Jindal and Vadim Koshkin join Petros Grivas to discuss their work to help identify potential biomarkers of response to enfortumab vedotin (EV) in patients with advanced urothelial carcinoma using a patient cohort in the UNITE dataset. The UNITE study researchers analyzed biomarkers associated with enfortumab vedotin (EV) treatment outcomes in patients with advanced urothelial carcinoma. They...
|
- Details
- Matt Galsky joins Sam Chang in a conversation about the long-term results of CheckMate 274, a randomized phase III study that enrolled patients with muscle-invasive urothelial cancer at high risk for recurrence after radical surgery. Patients were randomized to receive adjuvant nivolumab or placebo, with adjuvant nivolumab given for up to a year. The study's co-primary endpoints were disease-free...
|
- Details
- Srikala Sridhar joins Sam Chang in discussing long-term follow-up from the JAVELIN Bladder 100 trial of avelumab first-line maintenance for advanced urothelial carcinoma. The JAVELIN-100 study was conducted on patients with metastatic urothelial carcinoma who had received frontline platinum-based chemotherapy and achieved a disease response. These patients were then randomized to receive either av...
|
- Details
- Alicia Morgans is joined by Andrea Necchi in a conversation on the CheckMate 274 trial, the use of biomarkers in the adjuvant setting, and how they can be used to understand the effect of nivolumab. Necchi and colleagues performed an exploratory analysis to assess the association between disease-free survival (DFS) and biomarkers (continuous scale) and estimate treatment-effect hazard ratios for b...
|
- Details
- Alicia Morgans and Guru Sonpavde discuss the results of Cohort K of the EV-103 trial presented at the 2022 European Society for Medical Oncology (ESMO) Annual Congress. There remains a critical need for effective and tolerable first-line treatment options in locally advanced or metastatic urothelial cancer. In second and later-line settings, both EV and pembrolizumab have independently shown an ov...
|
- Details
- Jonathan Rosenberg joins Alicia Morgans to discuss long-term outcomes of enfortumab vedotin (EV) in patients with previously treated advanced urothelial carcinoma (UC) in the EV-301 trial. The EV-301 trial demonstrated improvements in progression-free and overall survival for patients with previously treated advanced UC who received EV compared to chemotherapy. In discussing how this updated analy...
|
